Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia
Main Article Content
Keywords
Intermediate, high-risk MDS, IPSS, lenalidomide, hematological response, dose-modified.
Abstract
No Abstract Available
Downloads
Download data is not yet available.
Abstract 843
PDF Downloads 544
HTML Downloads 305